Abstract
This open, parallel-group, multicenter study was conducted to compare the efficacy and safety of sotalol with that of quinidine for the prevention of atrial fibrillation relapse following DC conversion 183. DC-converted 183 patients with a 1- to 12-month history of atrial fibrillation were randomized to sotalol or quinidine after 2 hours of sinus rhythm following the conversion and followed on treatment for 6 months. The efficacy of sotalol and quinidine for the prevention of atrial fibrillation relapse during a 6-month period following DC conversion was similar. However, sotalol was better tolerated than quinidine.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
